Brief: Casi Pharmaceuticals Announces First Quarter 2023 Financial Results
17/05/2023 12:37
CASI Pharmaceuticals Inc CASI.O :
* CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023
FINANCIAL
RESULTS
* CASI PHARMACEUTICALS INC - CASH AND CASH EQUIVALENTS ARE
EXPECTED TO FUND CURRENT OPERATIONS BEYOND Q1 OF 2024
* CASI PHARMACEUTICALS INC - AS OF MARCH 31, 2023, CASI HAD
CASH,
CASH EQUIVALENTS, SHORT TERM INVESTMENTS AND LONG-TERM DEPOSIT
OF $44.8 MILLION
* CASI PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.45
Source text for Eikon: ID:nPnb8yS1ba
Further company coverage: CASI.O
Recent news on CASI Pharmaceuticals
See all newsBrief: Casi Pharmaceuticals Reports The Receipt Of Drug Registration Certificate For Thiotepa In China
CASI Pharmaceuticals Q3 revenue drops 60%, net loss widens
Brief: CASI Pharmaceuticals Inc Reports The Expiration Of Import Drug Registration License For Folotyn® In China
Casi Pharmaceuticals Inc Expected To Post A Loss Of 47 Cents A Share: Earnings Preview
Casi Pharmaceuticals Inc Reports Results For The Quarter Ended March 31: Earnings Summary